Avidicure, a biotechnology firm based in Amsterdam, has launched with $50 million in seed financing to develop innovative multifunctional antibodies, termed 'AVC-Boosters' for cancer treatment. Led by Arthur Lahr, the company aims to deliver safe, targeted cancer therapies leveraging the immune system. Their lead product, AVC-S-101, targets TROP2 for non-small cell lung cancer and other indications. Experts believe Avidicure's approach could position their antibodies as significant advancements in oncology, offering reduced toxicity and enhanced efficacy compared to existing therapies, making a marked difference in cancer treatment strategies.
AVC-Boosters have the potential to change the treatment landscape for a wide range of cancers as first-in-class multifunctional antibody products that safely mobilize the full power of the immune system.
Our products drive targeted and potent immune responses only in the tumor with reduced toxicity risk. We are eager to build a broad pipeline with our unique platform and progress our lead oncology product, AVC-S-101, into clinical development for solid tumors.
Avidicure is taking an entirely new approach with broad clinical potential. These products are well-positioned to make a significant impact in oncology.
Avidicure's multifunctional antibodies provide a novel treatment modality with a unique, differentiated mode of action, surpassing first-generation antibodies and other existing therapies.
Collection
[
|
...
]